Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/bcr1505.

Title:
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835] | Breast Cancer Research
Description:
Introduction Mucin 1 (MUC1) is a high molecular weight glycoprotein overexpressed on adenocarcinoma cells and is a target for immunotherapy protocols. To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and injection of oxidized mannan-MUC1. Method In a randomized, double-blind study, 31 patients with stage II breast cancer and with no evidence of disease received subcutaneous injections of either placebo or oxidized mannan-MUC1, to immunize against MUC1 and prevent cancer reoccurrence/metastases. Twenty-eight patients received the full course of injections of either oxidized mannan-MUC1 or placebo. Survival and immunological assays were assessed. Results After more than 5.5 years had elapsed since the last patient began treatment (8.5 years from the start of treatment of the first patient), the recurrence rate in patients receiving the placebo was 27% (4/15; the expected rate of recurrence in stage II breast cancer); those receiving immunotherapy had no recurrences (0/16), and this finding was statistically significant (P = 0.0292). Of the patients receiving oxidized mannan-MUC1, nine out of 13 had measurable antibodies to MUC1 and four out of 10 had MUC1-specific T cell responses; none of the placebo-treated patients exhibited an immune response to MUC1. Conclusion The results suggest that, in early breast cancer, MUC1 immunotherapy is beneficial, and that a larger phase III study should be undertaken.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {πŸ“š}

  • Health & Fitness
  • Science
  • Education

Content Management System {πŸ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 7,542,081 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {πŸ’Έ}

We find it hard to spot revenue streams.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {πŸ”}

patients, muc, cancer, pubmed, google, scholar, cas, article, responses, mfp, breast, apostolopoulos, patient, mckenzie, antibody, months, immune, cells, placebo, injection, samples, disease, study, cell, protein, years, table, response, immunotherapy, number, pietersz, tumour, pvntr, mucin, oxidized, antigen, positive, control, serum, vntr, mannan, immunized, trial, fusion, figure, mannanmuc, clinical, ifnΞ³, human, immunol,

Topics {βœ’οΈ}

endogenous immune response survival/disease-free interval advantage von mensdorff-pouilly oxidized mannan-muc1 [isrctn71711835] glutathione-s-transferase ifn human muc1 vaccines cross-linking mannose receptors early-stage breast cancer prevent cancer reoccurrence/metastases kaplan-meier survival curves high-molecular-weight glycoproteins hla-a2-restricted ctls double-blind pilot study article download pdf partial mastectomy anti-vntr antibody response superior clinical outcomes hla-a11-restricted epitope pre-existing peptide-reactive cell-mediated immune responses muc1-mannan fusion protein mannan-muc1 fusion protein monoclonal antibody co17-1a anti-muc1 vntr antibodies detect ifn-Ξ³ responses detectable anti-vntr antibody recombinant ny-eso-1 protein related subjects muc1-specific immune responses mhc-restricted ctl epitopes author information authors glutathione-s-transferase modified radical mastectomy vasso apostolopoulos affiliations immunology excised lymph nodes dissected lymph nodes early breast cancer m-fp clinical trials human ab serum anti-tumor response privacy choices/manage cookies primary breast cancer polymorphic epithelial mucin monoclonal antibodies reactive lymph nodes involved m-fp immunized patients muc1 cytotoxic t-cells humoral immune response m-fp vaccinated group

Questions {❓}

  • MUC1 in Cancer Immunotherapy β€” New Hope or Phantom Menace?

Schema {πŸ—ΊοΈ}

WebPage:
      mainEntity:
         headline:Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
         description:Mucin 1 (MUC1) is a high molecular weight glycoprotein overexpressed on adenocarcinoma cells and is a target for immunotherapy protocols. To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and injection of oxidized mannan-MUC1. In a randomized, double-blind study, 31 patients with stage II breast cancer and with no evidence of disease received subcutaneous injections of either placebo or oxidized mannan-MUC1, to immunize against MUC1 and prevent cancer reoccurrence/metastases. Twenty-eight patients received the full course of injections of either oxidized mannan-MUC1 or placebo. Survival and immunological assays were assessed. After more than 5.5 years had elapsed since the last patient began treatment (8.5 years from the start of treatment of the first patient), the recurrence rate in patients receiving the placebo was 27% (4/15; the expected rate of recurrence in stage II breast cancer); those receiving immunotherapy had no recurrences (0/16), and this finding was statistically significant (P = 0.0292). Of the patients receiving oxidized mannan-MUC1, nine out of 13 had measurable antibodies to MUC1 and four out of 10 had MUC1-specific T cell responses; none of the placebo-treated patients exhibited an immune response to MUC1. The results suggest that, in early breast cancer, MUC1 immunotherapy is beneficial, and that a larger phase III study should be undertaken.
         datePublished:2006-06-15T00:00:00Z
         dateModified:2006-06-15T00:00:00Z
         pageStart:1
         pageEnd:11
         license:http://creativecommons.org/licenses/by/2.0/
         sameAs:https://doi.org/10.1186/bcr1505
         keywords:
            Breast Cancer
            MUC1 Expression
            Partial Mastectomy
            Excise Lymph Node
            Endogenous Immune Response
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1505/MediaObjects/13058_2006_1474_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1505/MediaObjects/13058_2006_1474_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1505/MediaObjects/13058_2006_1474_Fig3_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Vasso Apostolopoulos
               affiliation:
                     name:Burnet Institute at Austin
                     address:
                        name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Geoffrey A Pietersz
               affiliation:
                     name:Burnet Institute at Austin
                     address:
                        name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anastasios Tsibanis
               affiliation:
                     name:Prolipsis Medical Center
                     address:
                        name:Prolipsis Medical Center, Athens, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Annivas Tsikkinis
               affiliation:
                     name:Prolipsis Medical Center
                     address:
                        name:Prolipsis Medical Center, Athens, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Heleni Drakaki
               affiliation:
                     name:Prolipsis Medical Center
                     address:
                        name:Prolipsis Medical Center, Athens, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bruce E Loveland
               affiliation:
                     name:Burnet Institute at Austin
                     address:
                        name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sara J Piddlesden
               affiliation:
                     name:Burnet Institute at Austin
                     address:
                        name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Magdalena Plebanski
               affiliation:
                     name:Burnet Institute at Austin
                     address:
                        name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Dodie S Pouniotis
               affiliation:
                     name:Burnet Institute at Austin
                     address:
                        name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael N Alexis
               affiliation:
                     name:The National Hellenic Research Foundation
                     address:
                        name:Institute of Biological Research and Biotechnology, The National Hellenic Research Foundation, Athens, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ian F McKenzie
               affiliation:
                     name:Burnet Institute at Austin
                     address:
                        name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Stamatis Vassilaros
               affiliation:
                     name:Prolipsis Medical Center
                     address:
                        name:Prolipsis Medical Center, Athens, Greece
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
      description:Mucin 1 (MUC1) is a high molecular weight glycoprotein overexpressed on adenocarcinoma cells and is a target for immunotherapy protocols. To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and injection of oxidized mannan-MUC1. In a randomized, double-blind study, 31 patients with stage II breast cancer and with no evidence of disease received subcutaneous injections of either placebo or oxidized mannan-MUC1, to immunize against MUC1 and prevent cancer reoccurrence/metastases. Twenty-eight patients received the full course of injections of either oxidized mannan-MUC1 or placebo. Survival and immunological assays were assessed. After more than 5.5 years had elapsed since the last patient began treatment (8.5 years from the start of treatment of the first patient), the recurrence rate in patients receiving the placebo was 27% (4/15; the expected rate of recurrence in stage II breast cancer); those receiving immunotherapy had no recurrences (0/16), and this finding was statistically significant (P = 0.0292). Of the patients receiving oxidized mannan-MUC1, nine out of 13 had measurable antibodies to MUC1 and four out of 10 had MUC1-specific T cell responses; none of the placebo-treated patients exhibited an immune response to MUC1. The results suggest that, in early breast cancer, MUC1 immunotherapy is beneficial, and that a larger phase III study should be undertaken.
      datePublished:2006-06-15T00:00:00Z
      dateModified:2006-06-15T00:00:00Z
      pageStart:1
      pageEnd:11
      license:http://creativecommons.org/licenses/by/2.0/
      sameAs:https://doi.org/10.1186/bcr1505
      keywords:
         Breast Cancer
         MUC1 Expression
         Partial Mastectomy
         Excise Lymph Node
         Endogenous Immune Response
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1505/MediaObjects/13058_2006_1474_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1505/MediaObjects/13058_2006_1474_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr1505/MediaObjects/13058_2006_1474_Fig3_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Vasso Apostolopoulos
            affiliation:
                  name:Burnet Institute at Austin
                  address:
                     name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Geoffrey A Pietersz
            affiliation:
                  name:Burnet Institute at Austin
                  address:
                     name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anastasios Tsibanis
            affiliation:
                  name:Prolipsis Medical Center
                  address:
                     name:Prolipsis Medical Center, Athens, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Annivas Tsikkinis
            affiliation:
                  name:Prolipsis Medical Center
                  address:
                     name:Prolipsis Medical Center, Athens, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Heleni Drakaki
            affiliation:
                  name:Prolipsis Medical Center
                  address:
                     name:Prolipsis Medical Center, Athens, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bruce E Loveland
            affiliation:
                  name:Burnet Institute at Austin
                  address:
                     name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sara J Piddlesden
            affiliation:
                  name:Burnet Institute at Austin
                  address:
                     name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Magdalena Plebanski
            affiliation:
                  name:Burnet Institute at Austin
                  address:
                     name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Dodie S Pouniotis
            affiliation:
                  name:Burnet Institute at Austin
                  address:
                     name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael N Alexis
            affiliation:
                  name:The National Hellenic Research Foundation
                  address:
                     name:Institute of Biological Research and Biotechnology, The National Hellenic Research Foundation, Athens, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ian F McKenzie
            affiliation:
                  name:Burnet Institute at Austin
                  address:
                     name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Stamatis Vassilaros
            affiliation:
                  name:Prolipsis Medical Center
                  address:
                     name:Prolipsis Medical Center, Athens, Greece
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:8
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Burnet Institute at Austin
      address:
         name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
         type:PostalAddress
      name:Burnet Institute at Austin
      address:
         name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
         type:PostalAddress
      name:Prolipsis Medical Center
      address:
         name:Prolipsis Medical Center, Athens, Greece
         type:PostalAddress
      name:Prolipsis Medical Center
      address:
         name:Prolipsis Medical Center, Athens, Greece
         type:PostalAddress
      name:Prolipsis Medical Center
      address:
         name:Prolipsis Medical Center, Athens, Greece
         type:PostalAddress
      name:Burnet Institute at Austin
      address:
         name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
         type:PostalAddress
      name:Burnet Institute at Austin
      address:
         name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
         type:PostalAddress
      name:Burnet Institute at Austin
      address:
         name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
         type:PostalAddress
      name:Burnet Institute at Austin
      address:
         name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
         type:PostalAddress
      name:The National Hellenic Research Foundation
      address:
         name:Institute of Biological Research and Biotechnology, The National Hellenic Research Foundation, Athens, Greece
         type:PostalAddress
      name:Burnet Institute at Austin
      address:
         name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
         type:PostalAddress
      name:Prolipsis Medical Center
      address:
         name:Prolipsis Medical Center, Athens, Greece
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Vasso Apostolopoulos
      affiliation:
            name:Burnet Institute at Austin
            address:
               name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Geoffrey A Pietersz
      affiliation:
            name:Burnet Institute at Austin
            address:
               name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
               type:PostalAddress
            type:Organization
      name:Anastasios Tsibanis
      affiliation:
            name:Prolipsis Medical Center
            address:
               name:Prolipsis Medical Center, Athens, Greece
               type:PostalAddress
            type:Organization
      name:Annivas Tsikkinis
      affiliation:
            name:Prolipsis Medical Center
            address:
               name:Prolipsis Medical Center, Athens, Greece
               type:PostalAddress
            type:Organization
      name:Heleni Drakaki
      affiliation:
            name:Prolipsis Medical Center
            address:
               name:Prolipsis Medical Center, Athens, Greece
               type:PostalAddress
            type:Organization
      name:Bruce E Loveland
      affiliation:
            name:Burnet Institute at Austin
            address:
               name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
               type:PostalAddress
            type:Organization
      name:Sara J Piddlesden
      affiliation:
            name:Burnet Institute at Austin
            address:
               name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
               type:PostalAddress
            type:Organization
      name:Magdalena Plebanski
      affiliation:
            name:Burnet Institute at Austin
            address:
               name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
               type:PostalAddress
            type:Organization
      name:Dodie S Pouniotis
      affiliation:
            name:Burnet Institute at Austin
            address:
               name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
               type:PostalAddress
            type:Organization
      name:Michael N Alexis
      affiliation:
            name:The National Hellenic Research Foundation
            address:
               name:Institute of Biological Research and Biotechnology, The National Hellenic Research Foundation, Athens, Greece
               type:PostalAddress
            type:Organization
      name:Ian F McKenzie
      affiliation:
            name:Burnet Institute at Austin
            address:
               name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
               type:PostalAddress
            type:Organization
      name:Stamatis Vassilaros
      affiliation:
            name:Prolipsis Medical Center
            address:
               name:Prolipsis Medical Center, Athens, Greece
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
      name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
      name:Prolipsis Medical Center, Athens, Greece
      name:Prolipsis Medical Center, Athens, Greece
      name:Prolipsis Medical Center, Athens, Greece
      name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
      name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
      name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
      name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
      name:Institute of Biological Research and Biotechnology, The National Hellenic Research Foundation, Athens, Greece
      name:Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, Australia
      name:Prolipsis Medical Center, Athens, Greece

External Links {πŸ”—}(176)

Analytics and Tracking {πŸ“Š}

  • Google Tag Manager

Libraries {πŸ“š}

  • Clipboard.js
  • Prism.js

CDN Services {πŸ“¦}

  • Crossref

4.62s.